tucatinib,neratinib,margetuximab,trastuzumab
seagen,puma,knight therapeutics,pierre fabre,macrogenics,zai lab
['triplet', 'neratinib', 'margetuximab', 'tucatinib', 'medsir']
what about after 2l? dr. curigliano shares his thoughts: - growing arsenal of antiher2 agents -preferred 3l: t-dm1 or tucatinib triplet
-neratinib (+cape), margetuximab(+chemo) or combos of trastuzumab &amp; chemo
-reasonable to keep her2-blockade across all line
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc